Celastrol Inhibits Migration, Proliferation and Transforming Growth Factor-Β2-induced Epithelial-Mesenchymal Transition in Lens Epithelial Cells.

Li-Ping Wang,Bao-Xin Chen,Yan Sun,Jie-Ping Chen,Shan Huang,Yi-Zhi Liu
DOI: https://doi.org/10.18240/ijo.2019.10.01
IF: 1.645
2019-01-01
International Journal of Ophthalmology
Abstract:AIMTo investigate the mechanism of celastrol in inhibiting lens epithelial cells (LECs) fibrosis, which is the pathological basis of cataract.METHODSHuman LEC line SRA01/04 was treated with celastrol and transforming growth factor-β2 (TGF-β2). Wound-healing assay, proliferation assay, flow cytometry, real-time polymerase chain reaction (PCR), Western blot and immunocytochemical staining were used to detect the pathological changes of celastrol on LECs. Then, we cultured Sprague-Dawley rat lens in medium as a semi-in vivo model to find the function of celastrol further.RESULTSWe found that celastrol inhibited the migration of LECs, as well as proliferation (P<0.05). In addition, it induced the G2/M phase arrest by cell cycle-related proteins (P<0.01). Moreover, celastrol inhibited epithelial-mesenchymal transition (EMT) by the blockade of TGF-β/Smad and Jagged/Notch signaling pathways.CONCLUSIONOur study demonstrates that celastrol could inhibit TGF-β2-induced lens fibrosis and raises the possibility that celastrol could be a potential novel drug in prevention and treatment of fibrotic cataract.
What problem does this paper attempt to address?